Aripiprazole, olanzapine and haloperidol pamoate salts
View Patent ↗The invention relates to the discovery that pamoate salts of haloperidol and aripiprazole result in a good to superior long acting and/or extended release profile. Thus, in one aspect of the invention, the invention includes pamoate salts of haloperidol or aripiprazole. Preferably, the pamoate salt is characterized by a ratio of haloperidol to pamoate of 1:1 or 2:1. The pamoate salt can be crystalline, such as a needle or a dense crystal, such as described in the Figures. The invention further relates to methods of treating an individual in need thereof comprising administering a pharmaceutical composition comprising a pamoate salt of haloperidol and aripiprazole.
1. A pamoate salt of haloperidol.
2. The pamoate salt of claim 1 wherein the ratio of haloperidol to pamoate is 1:1 or 2:1.
3. The pamoate salt of claim 1 wherein the salt is a needle.
4. The pamoate salt of claim 1 wherein the salt is crystalline.
5. A pamoate salt of aripiprazole.
6. The pamoate salt of claim 4 wherein the ratio of aripiprazole to pamoate is 1:1 or 2:1.
7. The pamoate salt of claim 5 wherein the salt is crystalline.
8. A method of treating an individual having psychotic diseases comprising administering a pharmaceutical composition comprising a pamoate salt of an active agent selected from the group consisting of haloperidol and aripiprazole.
9. The method of claim 8 wherein the composition is administered by injection.
10. The method of claim 8 wherein the composition is administered intramuscularly or subcutaneously.
11. The method of claim 8 wherein the composition releases an effective amount of the active agent over a period of at least about 24 hours.
12. The method of claim 8 wherein the composition releases an effective amount of the active agent over a period of at least about 48 hours.
13. The method of claim 8 wherein said composition consists essentially of the pamoate salt and a viscous aqueous carrier.
14. The method of claim 8 wherein the extended release formulation comprises a polylactide and the pamoate salt.
15. The method of claim 8 wherein the extended release formulation comprises a polylactide-co-glycolide and the pamoate salt.